EQS-News: Protalix and Chiesi Resubmit FDA Application For R

EQS-News: Protalix BioTherapeautics Inc. Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment 30.11.2022 / 21:00 CET/CEST The issuer is solely responsible for the content of this announcement. Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical co...

Related Keywords

Italy , United States , Israel , Brazil , Israeli , Dror Bashan , Chiesi Farmaceutici , Giacomo Chiesi , Chuck Padala , Protalix Biotherapeutics Inc , Company Website , Drug Administration , Nasdaq , Sangamo Therapeutics Inc , Distribution Services , Protalix Biotherapeautics Inc , Pfizer Inc , Protalix Biotherapeutics , Chiesi Group , News Service , Avrobio Inc , Freeline Therapeutics Holdings , Chiesi Resubmit , For Rare Disease Treatment , Chiesi Global Rare Diseases , Biologics License Application , Chief Executive , Sangamo Therapeutics , Corporate News , Regulatory Announcements , Chiesi , Resubmit , Fda , Application , Or , Mare , Disease , Treatment , Et Cest , The , Iotherapeutics , , Nc , American , Folx ,